Pharsight

Drugs that contain Moxifloxacin Hydrochloride

1. Avelox patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5607942 BAYER HLTHCARE 7-(1-pyrrolidinyl)-3-quinolone- and - naphthyridone-carboxylic acid derivatives as antibacterial agents and feed additives
Mar, 2014

(10 years ago)

US5849752 BAYER HLTHCARE Crystal modification of CDCH a process for its preparation and pharmaceutical formulations comprising this modification
Dec, 2016

(7 years ago)

US6610327 BAYER HLTHCARE Pharmaceutical moxifloxacin preparation
Oct, 2019

(4 years ago)

Drug Exclusivity Drug Exclusivity Expiration
M(M-185) Sep 27, 2019

Market Authorisation Date: 10 December, 1999

Treatment: Method of combating bacteria in a patient

Dosage: TABLET;ORAL

How can I launch a generic of AVELOX before it's drug patent expiration?
More Information on Dosage

AVELOX family patents

Family Patents

2. Avelox In Sodium Chloride 0.8% In Plastic Container patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5607942 BAYER HLTHCARE 7-(1-pyrrolidinyl)-3-quinolone- and - naphthyridone-carboxylic acid derivatives as antibacterial agents and feed additives
Mar, 2014

(10 years ago)

US5849752 BAYER HLTHCARE Crystal modification of CDCH a process for its preparation and pharmaceutical formulations comprising this modification
Dec, 2016

(7 years ago)

US6548079 BAYER HLTHCARE Moxifloxacin formulation containing common salt
Jul, 2020

(3 years ago)

Drug Exclusivity Drug Exclusivity Expiration
M(M-185) Sep 27, 2019

Market Authorisation Date: 30 November, 2001

Treatment: Method of combating bacteria in a patient

Dosage: SOLUTION;INTRAVENOUS

How can I launch a generic of AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER before it's drug patent expiration?
More Information on Dosage

AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER family patents

Family Patents

3. Moxeza patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5607942 HARROW EYE 7-(1-pyrrolidinyl)-3-quinolone- and - naphthyridone-carboxylic acid derivatives as antibacterial agents and feed additives
Mar, 2014

(10 years ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5607942

(Pediatric)

HARROW EYE 7-(1-pyrrolidinyl)-3-quinolone- and - naphthyridone-carboxylic acid derivatives as antibacterial agents and feed additives
Sep, 2014

(9 years ago)

US7671070 HARROW EYE Method of treating ophthalmic infections with moxifloxacin compositions
Sep, 2019

(4 years ago)

US6716830 HARROW EYE Ophthalmic antibiotic compositions containing moxifloxacin
Sep, 2019

(4 years ago)

US6716830

(Pediatric)

HARROW EYE Ophthalmic antibiotic compositions containing moxifloxacin
Mar, 2020

(4 years ago)

US7671070

(Pediatric)

HARROW EYE Method of treating ophthalmic infections with moxifloxacin compositions
Mar, 2020

(4 years ago)

US8450311 HARROW EYE Pharmaceutical compositions containing a fluoroquinolone antibiotic drug
May, 2029

(5 years from now)

US9114168 HARROW EYE Pharmaceutical compositions containing a fluoroquinolone antibiotic drug
May, 2029

(5 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Nov 19, 2013
Pediatric Exclusivity(PED) May 19, 2014

Market Authorisation Date: 19 November, 2010

Treatment: Method of combating bacteria in a patient

Dosage: SOLUTION/DROPS;OPHTHALMIC

How can I launch a generic of MOXEZA before it's drug patent expiration?
More Information on Dosage

MOXEZA family patents

Family Patents

4. Vigamox patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5607942 NOVARTIS 7-(1-pyrrolidinyl)-3-quinolone- and - naphthyridone-carboxylic acid derivatives as antibacterial agents and feed additives
Mar, 2014

(10 years ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5607942

(Pediatric)

NOVARTIS 7-(1-pyrrolidinyl)-3-quinolone- and - naphthyridone-carboxylic acid derivatives as antibacterial agents and feed additives
Sep, 2014

(9 years ago)

US7671070 NOVARTIS Method of treating ophthalmic infections with moxifloxacin compositions
Sep, 2019

(4 years ago)

US6716830 NOVARTIS Ophthalmic antibiotic compositions containing moxifloxacin
Sep, 2019

(4 years ago)

US6716830

(Pediatric)

NOVARTIS Ophthalmic antibiotic compositions containing moxifloxacin
Mar, 2020

(4 years ago)

US7671070

(Pediatric)

NOVARTIS Method of treating ophthalmic infections with moxifloxacin compositions
Mar, 2020

(4 years ago)

Market Authorisation Date: 15 April, 2003

Treatment: Method of combating bacteria in a patient

Dosage: SOLUTION/DROPS;OPHTHALMIC

How can I launch a generic of VIGAMOX before it's drug patent expiration?
More Information on Dosage

VIGAMOX family patents

Family Patents